Lipid digestion/absorption AnSci 520. Rumen Lipid Metabolism.
Pathophysio of Lipid Metabolism
-
Upload
mohammadislam87 -
Category
Documents
-
view
902 -
download
6
Transcript of Pathophysio of Lipid Metabolism
![Page 1: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/1.jpg)
Pathophysiology of lipid metabolismp y gy p
• Major plasma lipids are:Major plasma lipids are:– Cholesterol
Triglycerides– Triglycerides– Fatty acids
![Page 2: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/2.jpg)
Cholesterol Essential component of cell membranesRequired for biosynthesis of hormones
progesterone, cortisol, testosterone, estradiolAbsorbed through lumen of the gut, also secreted back to intestine as component of bile In addition to dietary sources, cholesterol is also synthesized by body tissues - liver
![Page 3: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/3.jpg)
Cholesterol Synthesis Essential during active growth or when dietary intake is limited Increases with a high-energy diet and in obesityEnzyme responsible (HMG-CoA reductase) can be inhibited
down-regulated when tissues are supplied with cholesterol in abundancesite of action for “statin” drugs
![Page 4: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/4.jpg)
TriglyceridesIdeal means of energy storageStored in fat cells: Adipose cell is made up of a rim of cytoplasm around a central droplet of energy-rich triglyceride Light in weight relative to energy content when compared to glycogen stores in liver or muscleTriglycerides stored in fat around internal organs serve as “cushions” and also provide layer of insulation
![Page 5: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/5.jpg)
Fatty AcidsTriglycerides are synthesized from fatty acids (circulating or from glucose)Enzyme lipoprotein lipase causes fatty acids to be released from glycerol (to which they are bound in the stored triglycerides)Free fatty acids bind to serum albumin
used as fuel/energy for muscle activityresynthesized and stored as a fuel source in adipocytestaken up by the liver or resynthesized back into triglycerides
![Page 6: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/6.jpg)
What are Lipoproteins?Cholesterol and triglycerides are insoluble, therefore are transported by lipoproteinsPolar surface of phospholipd allows lipoproteins to travel in aqueous environmentsLipoproteins are complex molecules that carry dietary and stored fat in plasma
triglyceride - rich (chylomicrons, VLDL-C)cholesterol - rich (LDL-C, HDL-C)
Each class varies in size, weight, lipid composition, density, apolipoprotein content
![Page 7: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/7.jpg)
What are Apolipoproteins?Proteins associated with lipoproteinsInvolved in:
secretion of lipoproteinsstructural integrity of lipoproteinco-activate enzyme reactions necessary for lipoprotein processing facilitate receptor-mediated uptake of lipoproteins and remnants
![Page 8: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/8.jpg)
Size & Density of Particles
![Page 9: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/9.jpg)
Lipoprotein Source Major LipidComponent Apolipoproteins
Chylomicrons Intestine TG A-I, A-II, A-IV, Cs,B-48, E
Very low densitylipoprotein(VLDL)
Liver TG B-100, Cs, E
Intermediatedensitylipoprotein (IDL)
Catabolism of VLDL CE B-100, Cs, E
Low densitylipoprotein (LDL) Catabolism of IDL CE B-100
High densitylipoprotein (HDL)
Liver, intestine,other CE, PL A-I, A-II, A-IV, C-I,
C-II, C-III, DTG=triglyceride; CE=cholesteryl ester; PL=phospholipid
Lipoprotein Classification
![Page 10: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/10.jpg)
Lipoprotein Classification
![Page 11: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/11.jpg)
ChylomicronsLargest lipoprotein particle
Produced in gut following absorption of digested fat
Triglyceride-rich particle
Hydrolyzed by lipoprotein lipase
Remnant particles removed by apoE receptors
![Page 12: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/12.jpg)
VLDL-CholesterolFatty acids bound to albumin in plasma are taken up by the liver and packaged into VLDL particles
Triglyceride-rich particle
Undergoes hydrolysis by lipoprotein lipase to render IDL
About half of IDL is converted to LDL by hepatic lipase; remaining IDL is taken up by liver
![Page 13: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/13.jpg)
LDL-CholesterolSmall enough to cross the capillary endothelium - the most atherogenic lipoprotein
LDL receptors migrate to cell surface to attract LDL
Heterogeneity in particle composition arises from differences in the amount of cholesterol per particle (small, dense LDL (“B”) vs. buoyant LDL (“A”)
![Page 14: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/14.jpg)
HDL-CholesterolReceives excess chol from tissues and transfers to liver LCAT increases the capacity of HDL to receive cholesterolThe esterification of free cholesterol into cholesteryl ester produces a more hydrophobic core - enhances HDL densityCETP mediates transfer of cholesterol ester form HDL core between HDL and other lipoproteins
![Page 15: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/15.jpg)
Apolipoproteins - ExamplesApoE (E2, E3, E4)
mediates uptake of remnant particles, either chylomicron remnants or VLDL (or IDL) remnants
ApoB-100present in VLDL and LDL - acts as ligand for the LDL receptor
ApoB-48found in chylomicrons and intestinal cells; lipoproteins coming from intestinal metabolism have ApoB-48; hepatic lipoproteins have ApoB-100
![Page 16: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/16.jpg)
Apolipoproteins - ExamplesApoC (CI, CII, CIII)
found on chylomicrons and VLDL particles. ApoCII activates lipoprotein lipase, catabolizing triglycerides. ApoCIII may inhibit action of lipoprotein lipase
ApoAIpresent in chylomicrons and HDL particles. Activates LCAT enzyme and provides structure to HDL particles
ApoAII present in chylomicrons and HDL particle. Activates hepatic lipase which results in HDL2 HDL3 nascent HDL
![Page 17: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/17.jpg)
What about Lipoprotein(a)?Lp(a) consists of one LDL particle covalently bound to one or two molecules of apo(a)Structurally very similar to plasminogen -appears to have both atherogenic and thrombogenic propertiesAssociated with increased cardiovascular disease risk
![Page 18: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/18.jpg)
Pathways of Lipid MetabolismExogenous
digestion and absorption of dietary fatEndogenous
cholesterol synthesis by the liver“Reverse” Cholesterol Transport
delivery of cholesterol from the tissues to the liver
![Page 19: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/19.jpg)
4. Decrease synthesis
3.Receptor uptake of LDL & remnant particles
1.Rate limiting enzyme-HMGCoA
2.Fecal excretion of bile acids
5. Increase LPL activity
![Page 20: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/20.jpg)
HDL Cholesterol Transport
![Page 21: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/21.jpg)
Putting it all together…...
![Page 22: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/22.jpg)
![Page 23: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/23.jpg)
![Page 24: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/24.jpg)
Primary DyslipidemiaAttributed to genetic causesPhysical manifestations of dyslipidemia important aspect of diagnosisMay only be expressed in the presence of exogenous or environmental factors (obesity, alcohol)Fredrickson Classification developed in the 1960’s
![Page 25: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/25.jpg)
Fredrickson classification of h li id ihyperlipidemias
PhenotypeLipoprotein(s)
l t dPlasma
h l t lPlasma
TGAthero-
i itRel.f Treatmentyp
elevated cholesterol TGs genicity freq. Treatment
I Chylomicrons Norm. to ↑ ↑↑↑↑–
pancreatiti <1% Diet controls
IIa LDL ↑↑ Norm. +++ 10%Bile acid sequestrants, statins, niacinstatins, niacin
IIb LDL and VLDL ↑↑ ↑↑ +++ 40% Statins, niacin, fibrates
III IDL ↑↑ ↑↑↑ +++ <1% Fibrates
IV VLDL Norm. to ↑ ↑↑ + 45% Niacin, fibrates
VVLDL and
↑ to ↑↑ ↑↑↑↑
+
5% Niacin, fibratesVchylomicrons
↑ to ↑↑ ↑↑↑↑ pancreatitis
5% ,
![Page 26: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/26.jpg)
![Page 27: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/27.jpg)
Primary hypercholesterolemiasy yp
G ti Disorder
Genetic defect
Inheritance Prevalence Clinical features
heteroz.:1/500 premature CAD (ages 30–50) TC 7 13 MFamilial hyper-
cholesterolemia LDL receptor dominant5% of MIs <60 yr
homoz.: 1/1 million
50) TC: 7-13 mM
CAD before age 18
TC > 13 mM
Familial defectiveapo B-100
apo B-100 dominant 1/700premature CADTC: 7-13 mM
Polygenic multiple commonpremature CAD
hypercholesterolemia
defects and mechanisms
variable 10% of MIs <60 yr
premature CADTC: 6.5-9 mM
Familial hyper-alphalipoprotein unknown variable rare
less CHD, longer lifel d
alphalipoproteinemia
unknown variable rareelevated HDL
![Page 28: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/28.jpg)
![Page 29: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/29.jpg)
![Page 30: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/30.jpg)
![Page 31: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/31.jpg)
Primary hypertriglyceridemiasy yp g y
Disorder Genetic defect Inheritance Prevalence Clinical features
LPL deficiency endothelial LPL recessiverare
1/1 million
hepatosplenomegalyabd. cramps, pancreatitis
TG: > 8.5 mM
Apo C-II rare abd cramps pancreatitisApo C IIdeficiency
Apo C-II recessiverare
1/1 millionabd. cramps, pancreatitis
TG: > 8.5 mM
Familial hyper-t i l id i
unknownenhanced
h ti TGdominant 1/100
abd. cramps, pancreatitisTG 2 3 6 Mtriglyceridemia hepatic TG-
production
dominant 1/100TG: 2.3-6 mM
![Page 32: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/32.jpg)
Primary mixed hyperlipidemiasy yp p
DisorderGenetic defect
Inheritance Prevalence Clinical features
Familial A EFamilial dysbeta-
lipoproteinemia
Apo E
high VLDL, chylo.
recessiverarely
dominant1/5000
premature CADTC: 6.5 -13 mM
TG: 2.8 – 5.6 mM
unknownFamilial
combined
unknown
high Apo B-100
dominant1/50 – 1/100
15% of MIs <60 yr
premature CADTC: 6.5 -13 mM
TG: 2.8 – 8.5 mM
![Page 33: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/33.jpg)
Secondary DyslipidemiaPrimary disease affects lipid metabolism, increasing serum lipid concentrationsIncreases levels of circulating lipoproteins, but may also alter chemical and physical propertiesMay accelerate the progress of the primary disease (e.g. renal, liver disease)May increase morbidity and mortality (e.g. diabetes, renal disease)
![Page 34: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/34.jpg)
Causes of Secondary Dyslipidemia…Endocrine
diabetesthyroid diseasepituitary diseasepregnancy
Renal nephrotic syndromechronic renal failure
Hepatic Cholestasis/ cholelithiasishepatocellular disease
Drugsß blockersthiazide diureticssteroid hormonesretinoic acid derivatives
NutitionalObesityalcohol
ImmunoglobulinmyelomaSLE
![Page 35: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/35.jpg)
Secondary hyperlipidemiasy yp p
Disorder VLDL LDL HDL Mechanism
Diabetes mellitus ↑ ↑ ↑ ↑ ↓ VLDL production ↑,LPL ↓, altered LDL
Hypothyreosis ↑ ↑ ↑ ↑ ↓ LDL-rec.↓, LPL ↓
Obesity ↑ ↑ ↑ ↓ VLDL production ↑
Anorexia - ↑ ↑ - bile secretion ↓, LDL catab. ↓
Nephrotic sy ↑ ↑ ↑ ↑ ↑ ↓ Apo B-100 ↑ LPL ↓ LDL-rec ↓Nephrotic sy ↑ ↑ ↑ ↑ ↑ ↓ Apo B 100 ↑ LPL ↓ LDL rec. ↓
Uremia, dialysis ↑ ↑ ↑ - ↓ LPL ↓, HTGL ↓ (inhibitors ↑)
Pregnancy ↑ ↑ ↑ ↑ ↑ oestrogen ↑Pregnancy ↑ ↑ ↑ ↑ ↑ VLDL production ↑, LPL ↓
Biliary obstructionPBC - - ↓ Lp-X ↑ ↑
no CAD; xanthomas
↑ ↑Alcohol ↑ ↑chylomicr. ↑ - ↑ dep. on dose, diet, genetics
Many-many drugs Please allways see for adverse effects before any drug presciption!!!
![Page 36: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/36.jpg)
Metabolic SyndromeRisk Factor Defining Level*
Abdominal ObesityWaist circ >102cm (men)Waist circ >88cm (women)
Triglyceride level > 1.7 mmol/L
HDL-Chol level< 1.0 mmol/L (men)< 1.3 mmol/L (women)
Blood Pressure > 130/85
Fasting Glucose Level 6.2 – 7.0 mmol/L
*Must have 3 or more
![Page 37: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/37.jpg)
![Page 38: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/38.jpg)
LDL Oxidation
High levels of LDL may result in higher levelsHigh levels of LDL may result in higher levelsof oxidized LDL in the sub-endothelial space• Scavenger Receptor (protein) on• Scavenger Receptor (protein) onmacrophages -binds to LDL particle that hasb difi dbeen modified• Monocytes and macrophages will function asPac-mans and clean cholesterols
![Page 39: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/39.jpg)
Oxidation of LDL (oxLDL)( )
Oxidation = process by which free radicals (oxidants) attack /and damage target molecules / tissues
Targets of free radical attack: DNA - carbohydrates Proteins - PUFA’s>>> MUFA’s>>>>> SFA’s
LDL can be oxidatively damaged: PUFA’s are oxidized and trigger oxidation of apoB100 protein --> oxLDL
OxLDL is engulfed by macrophages in subendothelial space
![Page 40: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/40.jpg)
LDL Oxidation
High levels of LDL may result in higher levelsHigh levels of LDL may result in higher levelsof oxidized LDL in the sub-endothelial space• Scavenger Receptor (protein) on• Scavenger Receptor (protein) onmacrophages -binds to LDL particle that hasb difi dbeen modified• Monocytes and macrophages will function asPac-mans and clean cholesterols
![Page 41: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/41.jpg)
Oxidation of LDL (oxLDL)( )
Oxidation = process by which free radicals (oxidants) attack /and damage target molecules / tissues
Targets of free radical attack: DNA - carbohydrates Proteins - PUFA’s>>> MUFA’s>>>>> SFA’s
LDL can be oxidatively damaged: PUFA’s are oxidized and trigger oxidation of apoB100 protein --> oxLDL
OxLDL is engulfed by macrophages in subendothelial space
![Page 42: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/42.jpg)
Atherosclerosis
![Page 43: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/43.jpg)
![Page 44: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/44.jpg)
![Page 45: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/45.jpg)
Atherosclerosis
![Page 46: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/46.jpg)
A Healthy Endotheliumproduces:
PGI2PGI2NO
Maintaining anMaintaining ananti-coagulant, anti-thromboticsurface
![Page 47: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/47.jpg)
A Dysfunctional Endotheliumhas decreased:
PGI2PGI2NO
Incpro-inflam
momo
TVCA
Shifting to a
VCA
pro-coagulant, pro-thrombotic surface
![Page 48: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/48.jpg)
Endothelial dysfunction is one of earliest changes in y gASMechanical, chemical, inflammatory mediators can trigger endothelial dysfunction:
High blood pressure S ki (f di l h id i l d Smoking (free radicals that oxidatively damage endothelium)Elevated homocysteineeva ed o ocys e eInflammatory stimuliHyperlipidemia
![Page 49: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/49.jpg)
Endothelial Dysfunction( endothelial activation, impaired ( , pendothelial-dependent vasodilation)
endothelial synthesis of PGI2 (prostacylcin), & NO y 2 (p y ),(nitric oxide)
PGI2 = vasodilator, platelet adhesion/aggregationNO = dil t l t l t & WBC ( t ) dh iNO = vasodilator, platelet & WBC (monocyte) adhesion
Adhesion of monocytes onto endothelium --> ytransmigration into subendothelial space (artery wall) --> change to macrophages
Endothelial dysfunction --> increased flux of LDL into artery wallartery wall
![Page 50: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/50.jpg)
![Page 51: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/51.jpg)
![Page 52: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/52.jpg)
Atherosclerosis
![Page 53: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/53.jpg)
Atherosclerosis
![Page 54: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/54.jpg)
![Page 55: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/55.jpg)
Atherosclerosis
![Page 56: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/56.jpg)
Atherosclerosis
![Page 57: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/57.jpg)
Atheroma
![Page 58: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/58.jpg)
![Page 59: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/59.jpg)
Atherosclerotic Plaqueq
Continued endothelial dysfunction (inflammatory response)Accumulation of oxLDL in macrophages (= foam cells) Migration and accumulation of:
h l llsmooth muscle cells, additional WBC’s (macrophages, T-lymphocytes)Calcific depositsChange in extracellular proteins, fibrous tissue formation
High risk = VLDL ( TG) LDL HDLHigh risk VLDL ( TG) LDL HDL
![Page 60: Pathophysio of Lipid Metabolism](https://reader033.fdocuments.in/reader033/viewer/2022051211/552844bb4a7959c93d8b4671/html5/thumbnails/60.jpg)